Bristol Myers Squibb announced that it invested $400 million to build a sterile drug product (SDP) facility in Dublin, Ireland. This Cruiserath facility will support the manufacturing and supply of existing medicines and serve as a launch excellence facility for pipeline assets. It marks the first European SDP facility for biologics manufacturing at Bristol Myers…
BMS sees new drug sales surge as Revlimid dips in Q3
Bristol-Myers Squibb (BMS) reported a mixed bag of results for the third quarter, with new drug sales up even as its popular blood cancer drug Revlimid fell 41% to $1.43 billion owing to generic competition. The anticoagulant Eliquis is in a similar position, but was also selected to be one of the first 10 drugs…
COVID-19 treatments will continue to lift pharma sector, according to Moody’s
The pandemic has eased throughout much of the world. But demand for COVID-19 vaccines and treatments continues to be brisk, according to ratings agency Moody’s. In general, the pandemic will contribute to the pharmaceutical industry’s projected EBITDA growth rate of 4% to 6% over the coming 12 to 18 months, the firm concluded. While a…
The top 5 pharma firms by reputation
Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance. Now ranked eighth overall, the pharma industry came in just ahead of…
Boehringer to settle thousands of cases that allege Pradaxa bleeding risk
Boehringer Ingelheim has reached an agreement in principle to settle some 2,935 lawsuits tied to its blood thinner Pradaxa (dabigatran etexilate). In a Connecticut Supreme Court filing, privately owned Boehringer (Ingelheim am Rhein, Germany) stated the settlement would resolve the lawsuits, which alleged the anticoagulant drug Pradaxa caused undisclosed bleeding risks. The company expects it will…
Bristol Myers Squibb’s Celgene acquisition fueled Q3 growth
Bristol Myers Squibb (NYSE:BMY) posted third-quarter results that beat analysts’ consensus forecast while raising its outlook for the remainder of the year. The New York City-headquartered company announced third-quarter revenues of $10.5 billion and profits of $1.63 per share for the quarter that ended Sept. 30, 2020 . Compared with the same quarter last year, profits…
Real estate firms tout former Bristol-Myers Squibb facility as an ‘innovation campus’
Lincoln Equities Group and H.I.G. Realty Partners announced today that they’ve acquired the 1.2 million-square-foot life sciences campus that Bristol-Myers Squibb owned outside Princeton, N.J. Brokerage firm JLL is helping the real estate outfits market the 433-acre “Princeton West Innovation Campus” in Hopewell, N.J., to life sciences companies as a secure, multipurpose research and development…